Danish Head And Neck Cancer Group

Patients with squamous cell carcinoma of the pharynx or larynx and an anticipated benefit of proton radiotherapy in reducing the risk of late dysphagia or xerostomia are randomized to proton or photon radiotherapy (2:1)

Summary Design Phase II observational
Treatment
* 60 Gy/50 fx / 10W-1 at 1.2 Gy/fx
o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively
* Proton radiotherapy
* Concomitant cisplatin for eligible patients*
* Nimorazole recommended for SCC* *The concurrent medical treatment (weekly cisplatin and nimorazole) are prescribed according to the national treatment guidelines, and are not part of the experimental treatment.
Endpoints
* Primary:
o Any new late toxicity grade >=3 according to CTC AE 5.0
* Secondary
* Side effects according to DAHANCA scoring system
* Quality of life and PROM according to EORTC C30 and HN43
* Loco-regional control (LRC)
* Overall survival (OS)

Weekly electronic reporting of patient-reported outcomes will be tested in a national trial in participants undergoing radiotherapy for head and neck cancer.
The study is a national study under the Danish Head and Neck Cancer Group (DAHANCA) and all 6 centers in Denmark will participate.
The clinical endpoints will be:
* Quality of life
* Objective toxicity score (DAHANCA)
* Opioid treatment
* Tube feeding
* Weight loss
* Hospitalization
* Compliance to treatment